clinical validation
Recently Published Documents


TOTAL DOCUMENTS

1784
(FIVE YEARS 579)

H-INDEX

73
(FIVE YEARS 12)

2022 ◽  
Vol 10 (1) ◽  
pp. 100461
Author(s):  
Pablo Vallejo-Medina ◽  
José Pablo Saffon ◽  
Ana Álvarez-Muelas

2022 ◽  
Vol 2 (1) ◽  
Author(s):  
Long T. Nguyen ◽  
Santosh R. Rananaware ◽  
Brianna L. M. Pizzano ◽  
Brandon T. Stone ◽  
Piyush K. Jain

Abstract Background The coronavirus disease (COVID-19) caused by SARS-CoV-2 has swept through the globe at an unprecedented rate. CRISPR-based detection technologies have emerged as a rapid and affordable platform that can shape the future of diagnostics. Methods We developed ENHANCEv2 that is composed of a chimeric guide RNA, a modified LbCas12a enzyme, and a dual reporter construct to improve the previously reported ENHANCE system. We validated both ENHANCE and ENHANCEv2 using 62 nasopharyngeal swabs and compared the results to RT-qPCR. We created a lyophilized version of ENHANCEv2 and characterized its detection capability and stability. Results Here we demonstrate that when coupled with an RT-LAMP step, ENHANCE detects COVID-19 samples down to a few copies with 95% accuracy while maintaining a high specificity towards various isolates of SARS-CoV-2 against 31 highly similar and common respiratory pathogens. ENHANCE works robustly in a wide range of magnesium concentrations (3 mM-13 mM), allowing for further assay optimization. Our clinical validation results for both ENHANCE and ENHANCEv2 show 60/62 (96.7%) sample agreement with RT-qPCR results while only using 5 µL of sample and 20 minutes of CRISPR reaction. We show that the lateral flow assay using paper-based strips displays 100% agreement with the fluorescence-based reporter assay during clinical validation. Finally, we demonstrate that a lyophilized version of ENHANCEv2 shows high sensitivity and specificity for SARS-CoV-2 detection while reducing the CRISPR reaction time to as low as 3 minutes while maintaining its detection capability for several weeks upon storage at room temperature. Conclusions CRISPR-based diagnostic platforms offer many advantages as compared to conventional qPCR-based detection methods. Our work here provides clinical validation of ENHANCE and its improved form ENHANCEv2 for the detection of COVID-19.


Eye ◽  
2022 ◽  
Author(s):  
Emma M. McVeigh ◽  
Siobhán M. Ludden ◽  
Sahra Mohamed ◽  
Nilpa Shah ◽  
Pádraig J. Mulholland ◽  
...  

Author(s):  
Kelly M. Schiabor Barrett ◽  
Max Masnick ◽  
Kathryn E. Hatchell ◽  
Juliann M. Savatt ◽  
Natalie Banet ◽  
...  

2022 ◽  
Vol 226 (1) ◽  
pp. S515
Author(s):  
Diana S. Abbas ◽  
Michelle Wang ◽  
Lindsey Claus ◽  
Akanksha Srivastava ◽  
Sara Young ◽  
...  

Author(s):  
Richard X. He ◽  
Danielle A. Hylton ◽  
Eric LR. Bédard ◽  
Scott Johnson ◽  
Bryce Laing ◽  
...  

2022 ◽  
pp. 160-174
Author(s):  
Fathima Mohammed Ahamed ◽  
Asiya Nazir

Extensive studies in the field of oncology are able to identify potential cancer biomarkers with tumor-specific molecular characteristics that exceed or complement those of existing biomarkers. However, there are challenges in the development and clinical validation of the cancer biomarkers due to the complexity of the biological process involved. Standalone or integrative approach of broad range of biomolecules, their expression pattern, epigenetic alterations, and metabolic effects are well studied in the cancer research. The potential cancer biomarkers need to be studied extensively with advanced technologies to bring about a great change in cancer screening and therapy. This chapter provide an overview on recent studies about potential cancer biomarkers. Also, specific characteristics of potential biomarkers in three common types of cancer are discussed.


Author(s):  
Olalla Calvo-Lozano ◽  
Miquel Sierra ◽  
Maria Soler ◽  
Maria Carmen Estévez ◽  
Luis Chiscano-Camón ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document